Drug intelligence / Profile preview

MTR107

Development stage: Unknown
Lead developer: Edith Wolfson Medical Center
Modality: Small Molecules
Administration: Intravenous

Overview

MTR107 is an injectable small molecule formulation of S-ethylisothiouronium diethylphosphate being developed for the prevention of intradialytic hypotension in patients with end-stage renal disease (ESRD) undergoing hemodialysis. It acts as a non-selective inhibitor of nitric oxide synthase (NOS), which helps maintain blood pressure by preventing the excessive vasodilation often triggered during the dialysis process. The drug was evaluated in Phase II clinical trials conducted by Wolfson Medical Center to determine its safety, pharmacokinetics, and efficacy in stabilizing blood pressure throughout hemodialysis sessions in patients predisposed to recurrent hypotensive episodes.

Other names: S-ethylisothiouronium diethylphosphateDifeturS-ethylisothiouronium phosphate

Targets

NOS1 (nNOS)

Beyond the preview

Go deeper on MTR107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTR107.

Explore the full profile